CTOs on the Move

Fresh Tracks Therapeutics

www.frtx.com

 
Fresh Tracks Therapeutics is a clinical-stage pharmaceutical company focused on transforming patient lives through the development of innovative and ground-breaking prescription therapeutics.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.frtx.com
  • 5777, Central Avenue
    Boulder, CO USA 80301
  • Phone: 720.505.4755

Executives

Name Title Contact Details

Similar Companies

Tioga Pharmaceuticals Inc

Tioga Pharmaceuticals Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Frontier Scientific

Frontier Scientific is a Logan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marker Therapeutics

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStartâ„¢ to improve the ability of the cellular immune system to recognize and destroy diseased cells.

Emendo Biotherapeutics

Emendo biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.

CPEX Pharmaceuticals

CPEX Pharmaceuticals is a Exeter, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.